565 related articles for article (PubMed ID: 32186711)
1. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
Diaz JH
J Travel Med; 2020 May; 27(3):. PubMed ID: 32186711
[TBL] [Abstract][Full Text] [Related]
2. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.
Usman MS; Siddiqi TJ; Khan MS; Ahmed A; Ali SS; Michos ED; Hall ME; Krasuski RA; Greene SJ; Butler J; Alkhouli M
Am J Cardiol; 2020 Sep; 130():159-161. PubMed ID: 32624189
[No Abstract] [Full Text] [Related]
3. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
Patel AB; Verma A
JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
[No Abstract] [Full Text] [Related]
4. COVID-19: The heart of the issue.
Woodward B; Kermali M
J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
[No Abstract] [Full Text] [Related]
5. Cardiovascular disease and the impact of COVID-19.
Yoganathan A; Sajjad MS; Harky A
J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
[No Abstract] [Full Text] [Related]
6. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
Dhawan R; Gundry RL; Brett-Major DM; Mahr C; Thiele GM; Lindsey ML; Anderson DR
J Mol Cell Cardiol; 2020 Jul; 144():12-14. PubMed ID: 32339565
[No Abstract] [Full Text] [Related]
7. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
[TBL] [Abstract][Full Text] [Related]
8. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
Sommerstein R; Kochen MM; Messerli FH; Gräni C
J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
[No Abstract] [Full Text] [Related]
9. Exercise as medicine for COVID-19: An ACE in the hole?
Heffernan KS; Jae SY
Med Hypotheses; 2020 Sep; 142():109835. PubMed ID: 32428811
[No Abstract] [Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.
Cure E; Cumhur Cure M
Diabetes Metab Syndr; 2020; 14(4):349-350. PubMed ID: 32311651
[TBL] [Abstract][Full Text] [Related]
11. Facts and reflections on COVID-19 and anti-hypertensives drugs.
Marin GH
Drug Discov Ther; 2020 May; 14(2):105-106. PubMed ID: 32213760
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
13. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.
Kai H; Kai M
Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442
[TBL] [Abstract][Full Text] [Related]
14. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
Tsioufis C; Dimitriadis K; Tousoulis D
Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334
[No Abstract] [Full Text] [Related]
15. Do ACE inhibitors and angiotensin receptor antagonists increase the risk of severe COVID-19?
Aamodt AH; Bjørk MH; Tronvik EA; Buanes EA; Stovner LJ; Atar D
Tidsskr Nor Laegeforen; 2020 Jun; 140(9):. PubMed ID: 32549022
[No Abstract] [Full Text] [Related]
16. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service.
Kim J; Kim DW; Kim KI; Kim HB; Kim JH; Lee YG; Byeon KH; Cheong HK;
J Korean Med Sci; 2020 Jun; 35(25):e232. PubMed ID: 32597045
[TBL] [Abstract][Full Text] [Related]
17. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
[TBL] [Abstract][Full Text] [Related]
18. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
19. Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Mackey K; Kansagara D; Vela K
Ann Intern Med; 2020 Sep; 173(5):W87. PubMed ID: 32701362
[No Abstract] [Full Text] [Related]
20. ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.
Onweni CL; Zhang YS; Caulfield T; Hopkins CE; Fairweather L; Freeman WD
Crit Care; 2020 Jul; 24(1):475. PubMed ID: 32736573
[No Abstract] [Full Text] [Related]
[Next] [New Search]